Iovance Biotherapeutics, Inc. (IOVA)

NASDAQ: IOVA · Real-Time Price · USD
2.490
+0.260 (11.66%)
At close: Jul 21, 2025, 4:00 PM
2.539
+0.049 (1.96%)
After-hours: Jul 21, 2025, 7:57 PM EDT
11.66%
Market Cap831.50M
Revenue (ttm)212.68M
Net Income (ttm)-375.36M
Shares Out 333.93M
EPS (ttm)-1.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume22,367,106
Open2.260
Previous Close2.230
Day's Range2.260 - 2.660
52-Week Range1.639 - 12.505
Beta0.85
AnalystsBuy
Price Target12.22 (+390.76%)
Earnings DateAug 7, 2025

About IOVA

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 838
Stock Exchange NASDAQ
Ticker Symbol IOVA
Full Company Profile

Financial Performance

In 2024, Iovance Biotherapeutics's revenue was $164.07 million, an increase of 13698.99% compared to the previous year's $1.19 million. Losses were -$372.18 million, -16.18% less than in 2023.

Financial Statements

Analyst Summary

According to 10 analysts, the average rating for IOVA stock is "Buy." The 12-month stock price target is $12.22, which is an increase of 390.76% from the latest price.

Price Target
$12.22
(390.76% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deliveri...

3 days ago - GlobeNewsWire

Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug

Iovance Biotherapeutics, Inc. stock is down nearly 30% since my "sell" recommendation in April. Q1 earnings disappointed, with Amtagvi sales underperforming the Street's expectations and guidance revi...

3 days ago - Seeking Alpha

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

SAN CARLOS, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona...

6 days ago - GlobeNewsWire

IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

LOS ANGELES , July 14, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violatio...

7 days ago - PRNewsWire

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma

61% Response Rate Observed in Third-Line or Earlier Patients SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focu...

7 days ago - GlobeNewsWire

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options

10 days ago - GlobeNewsWire

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.

SAN CARLOS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona...

11 days ago - GlobeNewsWire

IOVA COURT NOTICE: Iovance Biotherapeutics Investors may have been Affected by Fraud – Contact BFA Law by the July 14 Legal Deadline (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc. investors that lost money are notified to contact BFA Law before the July 14, 2025 securities fraud class action deadline.

11 days ago - GlobeNewsWire

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options If you purchased or acquire...

18 days ago - PRNewsWire

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure– Hagens Berman

IOVA Investors with Losses Encouraged to Contact Hagens Berman Before July 14th Deadline IOVA Investors with Losses Encouraged to Contact Hagens Berman Before July 14th Deadline

19 days ago - GlobeNewsWire

IOVA INVESTOR DEADLINE: Iovance Biotherapeutics Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc. investors that lost money are notified to contact BFA Law before the July 14, 2025 securities fraud class action deadline.

23 days ago - GlobeNewsWire

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit – IOVA

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).

25 days ago - GlobeNewsWire

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA

NEW YORK , June 26, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA durin...

25 days ago - PRNewsWire

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their Options

27 days ago - GlobeNewsWire

IOVA COURT REMINDER: Iovance Biotherapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and cert...

4 weeks ago - GlobeNewsWire

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure – Hagens Berman

SAN FRANCISCO, June 18, 2025 (GLOBE NEWSWIRE) -- Biotechnology firm Iovance Biotherapeutics Inc. (NASDAQ: IOVA) announced a significant leadership transition, confirming the resignation of Chief Finan...

4 weeks ago - GlobeNewsWire

IOVA NOTICE: Did Iovance Biotherapeutics, Inc. Mislead Investors? Contact BFA Law by July 14 Court Deadline if You Suffered Losses (NASDAQ:IOVA)

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and cert...

4 weeks ago - GlobeNewsWire

IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and cert...

5 weeks ago - GlobeNewsWire

IOVA LEGAL NOTICE: Lose Money when Iovance Biotherapeutics, Inc. Stock Plummeted 44%? Contact BFA Law by the July 14 Court Deadline (NASDAQ:IOVA)

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and cert...

5 weeks ago - GlobeNewsWire

Iovance Biotherapeutics to Present at Upcoming Conference

SAN CARLOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...

5 weeks ago - GlobeNewsWire

IOVA INVESTOR NEWS: Iovance Biotherapeutics, Inc. has been Sued for Securities Fraud – Contact BFA Law before July 14 Deadline (NASDAQ:IOVA)

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and cert...

6 weeks ago - GlobeNewsWire

IOVA LAWSUIT: Iovance Biotherapeutics, Inc. Lawsuit Alleges Securities Fraud Violations - Investors Notified to Contact BFA Law

NEW YORK, NY / ACCESS Newswire / June 4, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and c...

6 weeks ago - Accesswire

IOVA STOCK NOTICE: Iovance Biotherapeutics, Inc. Has Been Sued for Fraud; Investors Are Notified to Contact BFA Law Before July 14 Legal Deadline

NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ...

6 weeks ago - Accesswire